SynRinse Irrigation Pilot (SIP) Trial

Sinusitis, Chronic Clinical Trial

Official title: SynRinse Irrigation Pilot (SIP) Trial

Status Completed

Clinical Trial Summary

Assess if the use of SYNRINSE can improve short-term subjective and objective outcome measures after one week in patients with active Chronic Rhinosinusitis (CRS) who have had prior sinus surgery.

Clinical Trial Description

SYNRINSE is osmotically balanced and also contains soluble chitosan-argininamide, a modified natural glycopolymer that has a number of properties important to relieving the symptoms of mucus build up and bacterial biofilms. First, SYNRINSE reduces the viscosity of biofilms, the protective environment of infective bacteria that prevents topical antibiotics and other rinses to penetrate to reach the bacterial. By disrupting biofilms, SYNRINSE allows them to be cleared from the sinuses. Second, SYNRINSE has been shown to interact with the polymers comprise mucus, loosening thick, sticky layers and reducing their ability to adhere together and to mucosal surfaces. Third, all of the components in SYNRINSE are biocompatible and soothing to sensitive nasal cavities. ;

Related Conditions & MeSH terms

• Cystic Fibrosis
• Cystic Fibrosis With Other Manifestations
• Fibrosis
• Sinusitis
• Sinusitis, Chronic

• NCT number: NCT03154541
• Study type: Interventional
• Source: University of Washington
• Status: Completed
• Phase: Phase 1/Phase 2
• Start date: June 6, 2017
• Completion date: May 30, 2018